At nine months, 88% of 22 pancreatic cancer patients were alive without their cancer worsening.
Tango Therapeutics (TNGX) reported positive Phase 1/2 trial results for vopimetostat combined with RAS(ON) inhibitors in pancreatic cancer (PDAC) and lung cancer (NSCLC). 88% of PDAC patients showed no cancer progression at nine months. The company plans a Phase 3 trial in 2027. The FDA has indicated support for the combination therapy.
How this was made
The 30-second read
Why it matters
The data could accelerate the planned Phase 3 launch in 1H 2027 and improve the company's valuation.
Market read
First‑report of strong efficacy in a hard‑to‑treat cancer could drive biotech rally and influence investor sentiment toward similar targets.
What to watch
Regulatory timeline and potential competition from other PRMT5 programs may temper upside.
Background
Tango Therapeutics (NASDAQ:TNGX) is a clinical‑stage biotech focused on PRMT5 inhibition. The company announced updated Phase 1/2 data at the ESMO 2026 Congress.
Ticker impact
Tango Therapeutics disclosed positive Phase 1/2 data for its vopimetostat plus daraxonrasib combo in MTAP‑deleted pancreatic cancer, showing 88% 9‑month PFS and 82% ORR.
likely upward pressure as market prices in the encouraging efficacy and safety data.
First‑report of robust efficacy metrics for a late‑stage biotech candidate; investors typically reward such data.
Market effects
Strengthens the PRMT5 inhibitor space and may lift peer biotech valuations.
US biotech sector could see modest gains.
Highlights emerging targeted therapies for pancreatic cancer worldwide.
Counterpoint
If later‑stage data fails to confirm early signals, the stock could face a sharp correction.
Key entities
- companyTango Therapeutics, Inc.
Clinical‑stage biotech developing vopimetostat.
- companyRevolution Medicines
Partner providing the RAS(ON) inhibitors daraxonrasib and zoldonrasib.
